ProQR Therapeutics N.V Total Assets Growth & History (PRQR)
ProQR Therapeutics N.V's total assets was €112.8M for fiscal 2025.
View full ProQR Therapeutics N.V company overviewProQR Therapeutics N.V annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €112.8M | −€55.2M | −32.87% |
| 2024 | 2024-12-31 | €168.0M | €30.1M | +21.81% |
| 2023 | 2023-12-31 | €137.9M | −€33.4M | −19.52% |
| 2022 | 2022-12-31 | €171.3M | −€38.3M | −18.25% |
| 2021 | 2021-12-31 | €209.6M | €110.8M | +112.28% |
| 2020 | 2020-12-31 | €98.7M | −€18.8M | −16.00% |
| 2019 | 2019-12-31 | €117.5M | €7.3M | +6.63% |
| 2018 | 2018-12-31 | €110.2M | €57.1M | +107.58% |
| 2017 | 2017-12-31 | €53.1M | −€12.4M | −18.98% |
| 2016 | 2016-12-31 | €65.5M | — | — |
ProQR Therapeutics N.V quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €133.6M | −€4.0M | −2.90% |
| Q1 2026 | 2026-03-31 | €99.0M | −€52.7M | −34.71% |
| Q4 2025 | 2025-12-31 | €112.8M | −€55.2M | −32.87% |
| Q3 2025 | 2025-09-30 | €124.3M | €17.5M | +16.38% |
| Q2 2025 | 2025-06-30 | €137.5M | €19.5M | +16.51% |
| Q1 2025 | 2025-03-31 | €151.7M | €27.8M | +22.45% |
| Q4 2024 | 2024-12-31 | €168.0M | €30.1M | +21.81% |
| Q3 2024 | 2024-09-30 | €106.9M | −€35.2M | −24.77% |
| Q2 2024 | 2024-06-30 | €118.1M | −€29.9M | −20.23% |
| Q1 2024 | 2024-03-31 | €123.9M | −€34.1M | −21.60% |
| Q4 2023 | 2023-12-31 | €137.9M | −€33.4M | −19.52% |
| Q3 2023 | 2023-09-30 | €142.0M | €20.3M | +16.68% |
| Q2 2023 | 2023-06-30 | €148.0M | −€31.1M | −17.35% |
| Q1 2023 | 2023-03-31 | €158.0M | −€32.2M | −16.94% |
| Q4 2022 | 2022-12-31 | €171.3M | −€38.3M | −18.25% |
| Q3 2022 | 2022-09-30 | €121.7M | −€73.6M | −37.68% |
| Q2 2022 | 2022-06-30 | €179.1M | €16.7M | +10.28% |
| Q1 2022 | 2022-03-31 | €190.2M | — | — |
| Q4 2021 | 2021-12-31 | €209.6M | €110.8M | +112.28% |
| Q3 2021 | 2021-09-30 | €195.3M | €85.1M | +77.26% |
| Q2 2021 | 2021-06-30 | €162.4M | €68.9M | +73.64% |
| Q4 2020 | 2020-12-31 | €98.7M | −€18.8M | −16.00% |
| Q3 2020 | 2020-09-30 | €110.2M | €29.1M | +35.93% |
| Q2 2020 | 2020-06-30 | €93.5M | €3.2M | +3.60% |
| Q1 2020 | 2020-03-31 | €103.6M | — | — |
| Q4 2019 | 2019-12-31 | €117.5M | €7.3M | +6.63% |
| Q3 2019 | 2019-09-30 | €81.1M | — | — |
| Q2 2019 | 2019-06-30 | €90.3M | €52.7M | +140.41% |
| Q4 2018 | 2018-12-31 | €110.2M | €57.1M | +107.58% |
| Q2 2018 | 2018-06-30 | €37.5M | — | — |
| Q4 2017 | 2017-12-31 | €53.1M | −€12.4M | −18.98% |
| Q4 2016 | 2016-12-31 | €65.5M | — | — |
ProQR Therapeutics N.V total assets trends
Over the last five fiscal years, ProQR Therapeutics N.V's total assets increased from €98.7M to €112.8M, a change of €14.0M. The latest reported quarter, Q2 2026, shows €133.6M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ProQR Therapeutics N.V source filings ↗